Eszopiclone is the safest Z-drug for long-term use
Among the Z-drugs, eszopiclone is the only agent with evidence supporting long-term efficacy and safety, making it the preferred choice when extended treatment is necessary. 1
Evidence for Long-Term Use
The 2017 American Academy of Sleep Medicine guidelines specifically recommend eszopiclone for both sleep onset and sleep maintenance insomnia, with trials demonstrating efficacy at 2 mg and 3 mg doses 1. Critically, eszopiclone showed:
- 28-57 minutes improvement in total sleep time compared to placebo (95% CI: 18 to 76 min)
- 10-14 minutes reduction in wake after sleep onset (95% CI: 2 to 18 min)
- Moderate-to-large improvement in sleep quality 1
The American College of Physicians 2016 evidence report noted that eszopiclone improved both global and sleep outcomes, though they emphasized that most FDA-approved hypnotics are only indicated for short-term use 2. This is a critical caveat: the FDA has not formally approved any Z-drug for indefinite long-term use.
Why Not Zolpidem or Zaleplon?
Zolpidem has comparable short-term efficacy but lacks robust long-term safety data 1. The FDA label emphasizes short-term use, and observational studies link it to serious adverse effects including amnesia, vertigo, confusion, and complex sleep behaviors 2.
Zaleplon has an ultrashort half-life (~1 hour) making it suitable only for sleep onset problems, not maintenance 3. The FDA label explicitly states it is for short-term use and has not been adequately studied beyond 4 weeks 3.
Critical Safety Warnings for All Z-Drugs
Despite eszopiclone's relative advantage, all Z-drugs carry significant long-term risks:
- Increased all-cause mortality (HR = 1.600; 95% CI 1.027-2.491) 4
- Falls and fractures, particularly in older adults 5
- Dementia risk in observational studies 2
- Complex sleep behaviors including sleep-driving 6
- Cognitive impairment, though this appears less pronounced with Z-drugs than benzodiazepines 7
Practical Prescribing Algorithm
If long-term pharmacotherapy is unavoidable:
- Start with eszopiclone 2 mg (3 mg if 2 mg insufficient) for adults under 65 1, 8
- Use 1-2 mg maximum in elderly patients (≥65 years) due to increased exposure and prolonged elimination 8
- Avoid in severe hepatic impairment; use 2 mg maximum in mild-to-moderate hepatic disease 8
- Reassess necessity every 3-6 months and attempt discontinuation
- Monitor closely for falls, cognitive changes, and complex sleep behaviors
Common pitfall: Taking eszopiclone with or after a high-fat meal reduces efficacy by delaying absorption and reducing peak concentration by 21% 8. Instruct patients to take on an empty stomach immediately before bed.
Important caveat: The evidence shows that even with treatment, most patients continue to have sleep measures exceeding diagnostic thresholds—medications rarely achieve remission 2. Cognitive-behavioral therapy for insomnia (CBT-I) should always be considered first-line, with pharmacotherapy reserved for when non-pharmacologic approaches fail or as adjunctive therapy.